<Blinded Review: TIME_ANON_0528>
**Composite Score:** 6.8 / 10.0 (Rigor: 2.2/3.5 | Claims: 1.9/2.5 | Biology: 1.5/2.0 | Reproducibility: 1.2/2.0)
**Bias Category:** Statistical/Design
**Verdict:** Minor Revision
**Study Modality:** Hybrid Computational + Wet-Lab
**Technology Maturity:** Mid-Stage High-Throughput
**Epistemic Stage:** Basic/Mechanistic Discovery

OVERALL_SCORE: 6.8/10
VERDICT: PASS
ESTIMATED_DECADE: 2010s

---

### 1. Executive Summary / SUMMARY
This vascular biology study investigates the transcriptional regulation of the nitric oxide (NO)- and water-transporting transmembrane channel aquaporin-1 (`AQP1`) by the shear-stress-inducible atheroprotective transcription factor Krüppel-like factor 2 (`KLF2`) in human endothelial cells in vitro and across Virmani-classified stages of human atherosclerosis in vivo. Re-analyzing two prior microarray datasets (`[2]` from laser-microdissected human arterial endothelium overlying plaque-free vs. early/advanced lesions, and `[7]` from `KLF2`-overexpressing HUVECs over 24–72 h), the authors identify `AQP1` as the top-ranking cell-surface gene enriched in plaque-free endothelium (`Fig. 1A`) and fourth-ranking `KLF2`-induced gene (`p = 0.0007` correlation with `KLF2` mRNA, `Fig. 1B–C`). In primary HUVECs, `AQP1` mRNA (normalized to `P0`) is upregulated `3–4`-fold by prolonged laminar shear stress (`18 dyne/cm^2` for `>=4` days, `N = 6`), lentiviral `KLF2` overexpression (`N = 7`), or 24-hour atorvastatin treatment (`10 µM`, `N = 5`), whereas lentiviral shRNA knockdown of `KLF2` abrogates statin-mediated `AQP1` and `eNOS` induction (`N = 3`, `Fig. 2C`). Chromatin immunoprecipitation (`ChIP-qPCR`) in `KLF2-V5`-transduced HUVECs demonstrates a 6-fold enrichment (`p < 0.05`, `N = 3`) at an `rVISTA`-predicted `KLF` binding motif (`-422` to `-435 bp` upstream of the `AQP1` start codon, `Fig. 3`). Finally, `TNF-α` (`20 ng/ml`, 24 h) represses `AQP1` mRNA in HUVECs (`N = 4`, partially rescued by `KLF2` overexpression, `Fig. 4`), and paired immunohistochemistry on post-mortem human large arteries (`HAM56` for macrophages, `ICAM-1`, `CD31`, `α-SMA`, and `AQP1`) shows that endothelial `AQP1` protein is robustly expressed over plaque-free intimae and macrophage-poor (`SMC`-rich capped) advanced plaques, but is specifically lost over `ICAM-1+` inflamed, macrophage-rich early and advanced lesions (`Fig. 5`).

### 2. STRENGTHS
- **Coherent Multi-Modal Integration Across In Silico, In Vitro, and Human Tissue Levels:** The study logically connects human laser-capture microarray discovery (`Fig. 1`) to mechanical (`18 dyne/cm^2` flow), pharmacological (`atorvastatin`), and genetic (`KLF2` overexpression and `shRNA` silencing) perturbations in HUVECs (`Fig. 2`), direct promoter occupancy via `ChIP` (`Fig. 3`), inflammatory challenge (`TNF-α`, `Fig. 4`), and human arterial immunohistochemistry (`Fig. 5`).
- **Nuanced Interpretation of Advanced Plaque Heterogeneity:** Rather than forcing a simplistic binary between plaque-free and atherosclerotic vessels, the authors carefully distinguish macrophage-rich (`HAM56+`, `ICAM-1+`) vs. macrophage-poor (`SMC`-rich fibrous cap) regions within advanced human plaques (`Fig. 5C`), showing that `AQP1` tracks local non-inflamed endothelial status rather than gross plaque absence alone.

### 3. Methodological & Statistical Audit / WEAKNESSES & METHODOLOGICAL AUDIT
- **Lack of Sample Size (`N`) and Quantitative Scoring for Human Arterial Immunohistochemistry (`Fig. 5`):** While `Fig. 5A–C` and `S3–S5 Figs` present representative serial sections from an external iliac artery (plaque-free), abdominal aorta (early fatty streak), and common iliac artery (advanced fibro-calcific plaque), the manuscript never states how many independent human donors or arterial specimens were stained per Virmani stage, nor does it provide semi-quantitative scoring or statistical comparisons of `AQP1` / `ICAM-1` staining across patients.
- **Unadjusted Student's *t*-Tests Across Multi-Group Designs and Terminology Inconsistency:** In Materials and Methods (Line 62), the only statistical test described is the unpaired Student's *t*-test (`P < 0.05`). For multi-group factorial designs such as `Fig. 4` and `S2 Fig` (`mock vs. KLF2` × `vehicle vs. TNF-α`, `N = 4`), two-way ANOVA with post-hoc multiple-comparison correction should be used rather than pairwise *t*-tests. In addition, the Results text (Lines 78 and 90) repeatedly refers to `StepOne` SYBR Green real-time qPCR as `"semi-quantitative RT-PCR"`.
- **Absence of Functional NO Transport or Protein-Level Validation in HUVECs:** All in vitro HUVEC experiments (`Fig. 2` and `Fig. 4`) measure only `AQP1` mRNA via qPCR without Western blotting or surface flow cytometry to confirm `AQP1` protein induction/repression in cultured HUVECs, and no functional NO efflux assay is performed.

### 4. Biological / Experimental Grounding & Claim Proportionality
- **Claim 1:** `AQP1` is a direct transcriptional target of `KLF2` that is induced by laminar shear stress and statins and repressed by `TNF-α` in HUVECs. `[Well Supported]` — Supported by concordance across laminar shear, atorvastatin, lentiviral `KLF2` overexpression, `KLF2` shRNA knockdown (`Fig. 2`), `KLF2-V5` ChIP enrichment at `-422/-435 bp` (`Fig. 3`), and `TNF-α` challenge (`Fig. 4`).
- **Claim 2:** Endothelial `AQP1` protein expression in human large arteries marks non-activated (`ICAM-1-`) endothelium overlying plaque-free intimae and macrophage-poor advanced plaques, and is lost over macrophage-rich (`HAM56+`) inflamed lesions. `[Moderately Supported]` — Visually clear in the presented serial sections (`Fig. 5`, `S3–S5 Figs`), but lacks donor sample sizes (`N`) and quantitative immunohistochemical scoring across a cohort.

### 5. Reproducibility & Data Completeness
- **Primer & Antibody Reporting:** Complete qPCR (`AQP1`, `P0`, `eNOS`) and ChIP-PCR (`-378/-464` and `-33/-152`) primer sequences, antibody clones/catalog numbers (`V5 ab9116`, `AQP1 clone 1/A5F6`, `ICAM-1 clone My13`, `CD31 clone JC70A`, `HAM56`, `α-SMA clone 1A4`), and flow chamber parameters (`Ibidi µ-slide I 0.6 luer`, `18 dyne/cm^2`) are fully specified.
- **Missing Details:** The exact number of human post-mortem arterial donors examined by immunohistochemistry and the specific MISSION shRNA clone ID targeting `KLF2` are not reported.
</Blinded Review: TIME_ANON_0528>
